MBX Biosciences MBX 深 滬
等待開盤 09-23 09:30:00 美东时间
20.00
+10.000
+100.00%
華盛通- 最 高26.47
- 今 開22.40
- 成交量 2830.08万股
- 最 低 17.76
- 昨 收 10.00
- 總市值 6.72亿
- 52周最高 27.50
- 市盈率 靜 --
- 換手率 84.24%
- 52周最低 4.8069
- 委 比 50.00%
- 總股本 3359.39万
- 歷史最高 27.50
- 量 比 40.26
- 振 幅 87.10%
- 歷史最低 4.8069
- 每 手 1
- 風險率 5.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MBX Biosciences Announces Proposed Public Offering
MBX Biosciences, Inc. announced the filing of a Form S-1 registration statement with the SEC for a proposed underwritten public offering of 10,000,000 shares of its common stock, with an additional 1,500,000 shares purchasable by underwriters. The offering price remains undetermined, and the transaction is subject to market conditions. J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities are serving as joint book-running managers, while Ci...
09-22 20:14
Market-Moving News for September 22nd
MBX: 46% | MBX Biosciences shares are trading higher after the company announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic
09-22 19:26
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
MBX Biosciences announced positive results from its Phase 2 Avail™ trial of once-weekly canvuparatide in patients with chronic hypoparathyroidism (HP). The trial achieved the primary endpoint with 63% of patients meeting the prespecified composite endpoint at Week 12, and 79% of patients in the open-label extension (OLE) achieved responder status at 6 months. All 64 patients completed the 12-week study, and 94% enrolled in the OLE. Canvuparatide ...
09-22 11:00
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
MBX Biosciences will share topline results from its Phase 2 clinical trial of once-weekly canvuparatide for chronic hypoparathyroidism on September 22 and host a webcast at 8 am ET. Those interested can join via the provided link or dial-in numbers. The webcast and slides will be archived on the company’s website. MBX is a biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders. Media and investor co...
09-19 20:18
My Foodie Box Secures Interim Funding Amid Strategic Transition
My Foodie Box Limited ( ($AU:MBX) ) just unveiled an update. My Foodie Box Limi...
09-18 13:18
Microbix and Labquality Launch EQA Program for Accurate HPV-Related Cancer Diagnosis
Microbix Biosystms ( ($TSE:MBX) ) has provided an update. Microbix Biosystems I...
09-17 19:48
Guggenheim Remains a Buy on MBX Biosciences, Inc. (MBX)
Guggenheim analyst reiterated a Buy rating on MBX Biosciences, Inc. today and s...
09-15 18:55
SA Asks: Which biotechs could be acquired by year's end?
The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked Seeking Alpha analysts Stephen Ayers ...
09-14 04:18
Mbx Biosciences Announces That It Has Dosed The First Participant In Its Phase 1 Clinical Trial Of MBX 4291, A Precision Endocrine Peptide Prodrug That Acts As A GLP-1/GIP Co-Agonist Being Developed For The Treatment Of Obesity
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today
09-04 20:05
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
MBX Biosciences has initiated its Phase 1 clinical trial of MBX 4291, a novel GLP-1/GIP co-agonist prodrug candidate for obesity treatment. The trial aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug, which is designed for monthly administration, improved weight loss, and better gastrointestinal tolerability. The study includes single and multiple ascending dose evaluations, with topline results expected in 2...
09-04 12:00
